SCHEMBL3262365

SCHEMBL3262365

c1cnc(-n2cccc2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.44
ALDH1A1 P00352 5/20 0.41
MAPT P10636 4/20 0.41
KMT2A Q03164 3/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
MEN1 O00255 2/20 0.41
HPGD P15428 3/20 0.39
RPS6KA5 O75582 1/20 0.38
SLC6A7 Q99884 1/20 0.37
KDM4E B2RXH2 4/20 0.36
POLB P06746 4/20 0.34
LMNA P02545 1/20 0.34
HDAC8 Q9BY41 1/20 0.33
BLM P54132 1/20 0.33
HSP90AA1 P07900 1/20 0.33
USP2 O75604 1/20 0.32
PDE10A Q9Y233 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2146662 0.77 MAPT (0.42) MAPK1ALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL29405642 0.76 LMNA (0.40) MAPK1ALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL10099648 0.73 MAPK1 (0.42) MAPK1ALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL31659438 0.73 MAPT (0.35) ALDH1A1MAPTHPGDRPS6KA5KDM4E
SCHEMBL989991 0.73 CYP3A4 (0.52) MAPK1ALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL1763731 0.73 POLB (0.34) MAPK1ALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL9848539 0.71 ALDH1A1 (0.51) MAPK1ALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL7593026 0.71 ALDH1A1 (0.60) MAPK1ALDH1A1MAPTKMT2AL3MBTL1
SCHEMBL29955388 0.68 CA4 (0.32) POLB
SCHEMBL1437298 0.67 PLD1 (0.50) MAPK1ALDH1A1KMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220211706-A1 Methods and Compositions for Treating Cancer UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2022-07-07 US claimed
US-11285154-B2 Methods and compositions for treating cancer UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) 2022-03-29 US claimed
EP-3600302-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER United States Government as Represented by The Department of Veterans Affairs (US) 2020-02-05 EP claimed
US-20190231778-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2019-08-01 US claimed
WO-2018183762-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) 2018-10-04 WO claimed
US-20240217969-A1 SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-07-04 US disclosed
EP-4313971-A1 SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2024-02-07 EP disclosed
CN-117157289-A Substituted pyrrolecarboxamides, process for their preparation and their use as kinase inhibitors 内尔维亚诺医疗科学公司 2023-12-01 CN disclosed
US-20220372135-A1 METHODS FOR TREATING MYELOFIBROSIS AND RELATED CONDITIONS DISC MEDICINE, INC. (US) 2022-11-24 US disclosed
WO-2022207404-A1 SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2022-10-06 WO disclosed
CN-114773314-A Biarylaminoguanidine derivative 上海拓界生物医药科技有限公司 2022-07-22 CN disclosed
US-20220211706-A1 Methods and Compositions for Treating Cancer UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2022-07-07 US disclosed
US-6919347-B2 Bradykinin B1 receptor antagonists PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2005-07-19 US disclosed
CN-1148367-C Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same ��ѧ�о���Ӧ����ѯ��˾ 2004-05-05 CN disclosed
US-20030229092-A1 Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens PHARMACOPEIA, INC. (US) 2003-12-11 US disclosed
EP-1196411-B1 BRADYKININ B1 RECEPTOR ANTAGONISTS PHARMACOPEIA INC (US) 2003-09-17 EP disclosed
EP-1196411-A1 BRADYKININ B1 RECEPTOR ANTAGONISTS PHARMACOPEIA, INC. (US) 2002-04-17 EP disclosed
CN-1324353-A Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same SOD CONSEILS RECH APPLIC (FR) 2001-11-28 CN disclosed
WO-2001005783-A1 BRADYKININ B1 RECEPTOR ANTAGONISTS PHARMACOPEIA, INC. (US) 2001-01-25 WO disclosed
CN-1177354-A Pyrimido [4, 5 -b] indoles UPJOHN CO (US) 1998-03-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229092-A1 Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens BDKRB1, BDKRB2, HRH2 MAPK1 659/4885ALDH1A1 2408/4885MAPT 4096/4885
US-20240217969-A1 SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS CDC7, CDK7, CDK17 MAPK1 301/4885ALDH1A1 4472/4885MAPT 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.